Maersk’s Stillstrom Unveils Standalone Offshore Charging Solutions for Vessels
Published
Apr 21, 2026 5:08 am ET
Illustration of Power Hub (Credit: Stillstrom)
…
Novo Nordisk touts Phase III success for etavopivat
Danish pharma major Novo Nordisk (NOV: N) today announced the top-line results from HIBISCUS, a pivotal Phase III…
Fresh study data pushes Novo Nordisk to double down on similar projects
I want to receive customized email newsletters from Watch Medier A/S , including information about our brands and…
A dozen banks want a euro stablecoin. Fireblocks is making it happen
Cryptocurrency custody firm Fireblocks is handling the issuance and distribution of a euro-denominated stablecoin, backed by a group…
Here’s Why Agios Pharmaceuticals Crashed 23% Today
Key Points Agios Pharmaceuticals shares dropped 23% following Novo Nordisk’s trial results. Novo’s etavopivat outperformed Agios’ mitapavit in…
Novo Nordisk’s Rare Disease Breakthrough Fails to Lift Oversold Shares
Novo Nordisk reports positive Phase 3 results for sickle cell drug etavopivat, but shares remain under pressure from…
St Joseph’s Crossmaglen win the Danske Bank Ennis Cup – The Irish News
Danske Bank Ennis Cup final: St Joseph’s, Crossmaglen 7-9 St Louis, Kilkeel 6-5 A STRONG final quarter from…
DFDS INITIATES CEO SUCCESSION PROCESS
COMPANY ANNOUNCEMENT no. 34 – 6 November 2025 The Board of Directors has initiated a search for a…
Jefferies forecasts potential sales of USD 1 billion
Editor Ulrich Quistgaard Tel.: +45 3330 8349 We take responsibility for the content and are signed up to Pressenævnet…
Lagarde signals no near-term rate move – Danske Bank
Danske Research Team highlights that ECB President Christine Lagarde sees the economic fallout from the Iran war as…
Damaged Ferries Set to Return in May as Sailings Face Further Disruption
Two vessels taken out of service following separate incidents are expected to return to operation in May, ferry…
Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…